
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine

Rinvoq is the first and only systemic medication approved in the EU for NSV

The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer

The company will gain a novel oral treatment for lung cancer

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

Cases of measles have been rising in Europe since 2023

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

Plaque psoriasis affects over 125 million people worldwide

The autoimmune disease affects approximately three to five million people globally

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable